Researchers from the University of California, San Francisco, and Bio-Rad have demonstrated that Bio-Rad’s Droplet Digital PCR (ddPCR) technology can dramatically improve the sensitivity, precision, and throughput of a popular assay for telomerase activity.
Currently, researchers are investigating telomerase activity as a biomarker for cancer diagnosis and as a target for anticancer drugs. Measuring it’s activity more sensitivity may enhance our understanding of it’s role in diseases.
This research was presented at the American Association of Cancer Research (AACR) Annual Meeting on Tuesday, April 9.
You can view the press release here: http://bit.ly/12KJyUk
Tags: Bio-Rad, droplet digital pcr